Epigenetic mechanisms in cancer

Epigenetic mechanisms in cancer

Epigenetic mechanisms in cancer

On this page

Epigenetics Overview - The Cancer Conductor

Heritable, reversible changes in gene expression without altering the DNA sequence. These modifications can silence tumor suppressor genes or activate oncogenes, acting as a conductor for carcinogenesis.

  • Key Mechanisms:
    • DNA Methylation: Hypermethylation of CpG islands in promoter regions → silences tumor suppressor genes (e.g., CDKN2A).
    • Histone Modification: Altered acetylation/deacetylation patterns change chromatin accessibility and gene expression.

⭐ Epigenetic alterations are reversible, forming a basis for novel cancer therapies (e.g., DNMT and HDAC inhibitors).

Epigenetic Mechanisms in Cancer: DNA, Histone, and RNA

DNA Methylation - The Master Switch

  • Mechanism: Covalent addition of a methyl group ($CH_3$) to cytosine, primarily at CpG dinucleotides.
  • Enzyme: Catalyzed by DNA Methyltransferases (DNMTs).
  • Function: Acts as a master switch for gene expression.
    • ↑ Methylation (Hypermethylation) → condensed chromatin → gene silencing.
    • ↓ Methylation (Hypomethylation) → relaxed chromatin → gene activation.

Epigenetic mechanisms in cancer development

  • Role in Cancer:
    • Hypermethylation: Silences tumor suppressor genes (e.g., p16, BRCA1).
    • Hypomethylation: Activates oncogenes and promotes genomic instability.

High-Yield: Aberrant hypermethylation of CpG islands in the promoter regions of tumor suppressor genes is a hallmark of many cancers, leading to their transcriptional inactivation.

Histone Modification - Unspooling Trouble

  • Core Concept: Chemical changes to histone proteins alter chromatin structure & gene accessibility. Tightly wound heterochromatin silences genes; loosely packed euchromatin allows transcription.

  • Key Modifications:

    • Acetylation: Histone Acetyltransferases (HATs) add acetyl groups → relaxed chromatin (euchromatin) → gene expression. Histone Deacetylases (HDACs) reverse this.
    • Methylation: Histone Methyltransferases (HMTs) add methyl groups. Effect varies: can activate or repress genes depending on the site.
  • Role in Cancer:

    • Mutations in genes for HATs/HDACs or HMTs can silence tumor suppressor genes (e.g., p53) or activate oncogenes.

Histone modifications and binding proteins

Exam Favorite: Histone Deacetylase (HDAC) inhibitors (e.g., Vorinostat, Romidepsin) are a class of anti-cancer drugs. They work by promoting histone acetylation, leading to re-expression of silenced tumor suppressor genes.

Epigenetic Drugs - Hacking the Code

Goal: Reactivate tumor suppressor genes silenced by epigenetic modifications.

  • DNMT Inhibitors: Azacitidine, Decitabine. Hypomethylating agents that incorporate into DNA, trapping DNMTs and leading to ↓ methylation.
  • HDAC Inhibitors: Vorinostat, Romidepsin. Prevent removal of acetyl groups from histones, leading to ↑ acetylation, open chromatin, and gene expression.

Azacitidine and Decitabine are workhorses for myelodysplastic syndromes (MDS), often improving blood counts and delaying progression to acute myeloid leukemia (AML).

  • DNA hypermethylation at CpG islands in promoter regions silences tumor suppressor genes (e.g., MLH1, BRCA1).
  • Widespread genomic hypomethylation can lead to chromosomal instability and activation of proto-oncogenes.
  • Histone modifications, like deacetylation, can condense chromatin and inhibit transcription of key regulatory genes.
  • MicroRNAs (miRNAs) can function as oncogenes or tumor suppressors by regulating mRNA translation.
  • Unlike genetic mutations, epigenetic alterations are potentially reversible, offering novel therapeutic targets (e.g., DNMT and HDAC inhibitors).

Practice Questions: Epigenetic mechanisms in cancer

Test your understanding with these related questions

A 65-year-old man comes to the physician because of a 1-month history of progressive back pain. He has also had a 5-kg (11-lb) weight loss over the past 3 months. His only medications are a daily multivitamin and ibuprofen, which he takes daily for the back pain. Physical examination shows tenderness to palpation over the lower spine and the left iliac crest. His hemoglobin concentration is 9.3 g/dL, his serum calcium concentration is 12 mg/dL, and his serum creatinine concentration is 2.1 mg/dL. A bone marrow biopsy shows 21% plasma cells. A diagnosis of multiple myeloma is established. In preparation for an autologous hematopoietic stem cell transplantation, the patient receives a myeloablative treatment regimen that includes busulfan. Which of the following drugs acts via a similar mechanism of action to busulfan?

1 of 5

Flashcards: Epigenetic mechanisms in cancer

1/10

If a patient inherits or develops a mutation in a _____ gene, the complementary allele must be deleted/mutated before cancer develops

TAP TO REVEAL ANSWER

If a patient inherits or develops a mutation in a _____ gene, the complementary allele must be deleted/mutated before cancer develops

tumor suppressor

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial